Circulation Research · 2008 · 193 citations · 16 references
Life SciencesMolecular BiologyObstetricsCell SignalingGene ExpressionSignal TransductionAngiogenesisGrowth Factor SignalingPlacental BiologyPlacental DevelopmentPlacental PhysiologyPregnancy PhysiologyCell Type-specific SignalingSplicing Variant AnalysisTissue-specific SplicingVascular Endothelial Growth FactorVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor SignalingVascular Smooth Muscle RegulationVegf Pathway Inhibition
A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in nonendothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect nonendothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.
16
Sharon E. Maynard, Jiang-Yong Min, Jaime R. Merchan et al. · Journal of Clinical Investigation · 2003 · 4K citations · Full text
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Napoleone Ferrara, Karen Carver-Moore, Helen Chen et al. · Nature · 1996 · 3.7K citations · Full text
Circulating Angiogenic Factors and the Risk of Preeclampsia
Richard J. Levine, Cong Qian, Lucinda J. England et al. · New England Journal of Medicine · 2004 · 3.6K citations · Full text
Circulating angiogenic factors and the risk of preeclampsia*
Obstetrics and Gynecology · 2004 · 2.6K citations
Medicine, Gynecology, Obstetrics +14
Autocrine VEGF Signaling Is Required for Vascular Homeostasis
Sunyoung Lee, Tom T. Chen, Chad L. Barber et al. · Cell · 2007 · 1K citations · Full text